Ultrastructural basis of enhanced antitumor cytotoxicity of cord blood-derived CTLs: a comparative analysis with peripheral blood and bone marrow.

Umbilical cord blood cells (UCBC) are a rich source of immature immune effector and accessory cells, including dendritic cells. UCBC-derived cytotoxic T lymphocytes (CTLs) generated against human breast cancer or neuroblastoma have shown an increased tumor-specific cytotoxicity compared to peripheral blood (PB)-derived CTLs. The precise mechanism of this increased cytotoxicity is not known. Since dendritic cells (DCs) play a central role in the immunostimulation, we compared the ultrastructure and antigen presenting nature of DCs from UCBC, PB and bone marrow (BM) at various stages of maturation using scanning and transmission electron microscopy as well as fluorescent microscopy to elucidate the mechanism underlying the increased cytotoxicity of UCBC-derived CTLs. DCs were examined for their immunophenotype nuclear morphology, dendritic processes and cytoplasmic endosomal vesicles after 0, 3, 7 and 10 days in culture with antigen priming on day 6. Results showed that there were smaller and more vesicles in UCB-DCs compared to DCs from the other two sources, while the endosomal vesicles in PB-DCs were heterogenous in size. The antigen processing ability of the UCB-DCs showed an increase in antigen-positive endosomes compared to PB-DCs as determined by the fluorescent microscopy. Thus, our results provided the comparative analyses of DCs from cord blood, peripheral blood and bone marrow, and suggested that UCBC-DCs might have better antigen presenting ability leading to increased CTL-mediated antitumor cytotoxicity.

[1]  J. Kurtzberg,et al.  Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. , 1989, The New England journal of medicine.

[2]  J. Vose,et al.  Dendritic cell-based therapy for mantle cell lymphoma. , 2006, International journal of oncology.

[3]  Franco Locatelli,et al.  Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Kurtzberg,et al.  Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. , 1990, International journal of cell cloning.

[5]  J. Armitage,et al.  The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. , 1991, Blood.

[6]  J. Wagner,et al.  Adult umbilical cord blood transplantation: a comprehensive review , 2006, Bone Marrow Transplantation.

[7]  J. Dick,et al.  Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. , 1997, Blood.

[8]  Adrian P Gee,et al.  Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. , 2005, Blood.

[9]  R. Burt,et al.  Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. , 2008, JAMA.

[10]  D. Soll,et al.  Changes in the motility, morphology, and F-actin architecture of human dendritic cells in an in vitro model of dendritic cell development. , 2000, Cell motility and the cytoskeleton.

[11]  D. Harris,et al.  Umbilical cord blood: a unique source of pluripotent stem cells for regenerative medicine. , 2007, Current stem cell research & therapy.

[12]  S. Joshi,et al.  Cytotoxicity of Cord Blood Derived Her2/neu-specific Cytotoxic T Lymphocytes against Human Breast Cancer in vitro and in vivo , 2004, Breast Cancer Research and Treatment.

[13]  F. Sallusto,et al.  Origin, maturation and antigen presenting function of dendritic cells. , 1997, Current opinion in immunology.

[14]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[15]  A. Beutler,et al.  Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma , 2004, Anti-cancer drugs.

[16]  G. Kollias,et al.  Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. , 2003, Immunity.

[17]  B. Ludewig,et al.  Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma , 2006, Cancer Immunology, Immunotherapy.

[18]  J. Huber,et al.  Ex-vivo expanded umbilical cord blood stem cells retain capacity for myocardial regeneration. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[19]  J. Jackson,et al.  Functional and phenotypic characterization of human peripheral blood stem cell harvests: a comparative analysis of cells from consecutive collections. , 1995, Blood.

[20]  H. Ueno,et al.  Immune and Clinical Outcomes in Patients with Stage IV Melanoma Vaccinated with Peptide-Pulsed Dendritic Cells Derived From CD34+ Progenitors and Activated with Type I Interferon , 2005, Journal of immunotherapy.

[21]  Junbiao Chang,et al.  Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathy. , 2008, Reproductive biomedicine online.

[22]  Tianlun Yang,et al.  Transplantation of human umbilical cord blood cells for the repair of myocardial infarction. , 2008, Medical science monitor : international medical journal of experimental and clinical research.

[23]  A. Aguirre,et al.  Dendritic cell immunizations alone or combined with low doses of interleukin‐2 induce specific immune responses in melanoma patients , 2005, Clinical and experimental immunology.

[24]  E. Gluckman,et al.  Cord blood transplantation: state of the art , 2009, Haematologica.

[25]  Wei-Chen Lee,et al.  Vaccination of Advanced Hepatocellular Carcinoma Patients with Tumor Lysate-Pulsed Dendritic Cells: A Clinical Trial , 2005, Journal of immunotherapy.

[26]  D. Harris,et al.  Analysis of the alloreactive capacity of human umbilical cord blood: implications for graft-versus-host disease. , 1994, Bone marrow transplantation.

[27]  K. Roszek,et al.  [Regulation and direction of umbilical cord blood stem cells differentiation and their therapeutic application]. , 2008, Postepy higieny i medycyny doswiadczalnej.

[28]  S. Aamdal,et al.  Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients , 2005, British Journal of Cancer.

[29]  O. Hegre,et al.  Dendritic cell/lymphocyte clustering: Morphologic analysis by transmission electron microscopy and distribution of gold‐labeled MHC class II antigens by high‐resolution scanning electron microscopy , 1993, The Anatomical record.

[30]  S. Zang,et al.  Umbilical cord blood transplantation in adult myeloid leukemia , 2008, Bone Marrow Transplantation.

[31]  K. Theilgaard-Mönch,et al.  Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts , 2001, Bone Marrow Transplantation.

[32]  S. Joshi,et al.  Immunotherapy of Human Neuroblastoma Using Umbilical Cord Blood-Derived Effector Cells , 2007, Journal of Neuroimmune Pharmacology.

[33]  Clive Wasserfall,et al.  Autologous umbilical cord blood infusion for type 1 diabetes. , 2008, Experimental hematology.

[34]  C. Verfaillie,et al.  A multifactorial analysis of umbilical cord blood, adult bone marrow and mobilized peripheral blood progenitors using the improved ML-IC assay. , 2005, Experimental hematology.

[35]  M. Bishop,et al.  Antitumor activity of human umbilical cord blood cells: A comparative analysis with peripheral blood and bone marrow cells. , 1998, International journal of oncology.

[36]  S. Joshi,et al.  Enhanced in vitro and in vivo cytotoxicity of umbilical cord blood cells against human breast cancer following activation with IL-15 and colony stimulating factors. , 2002, In vivo.

[37]  F. Koning,et al.  Morphological changes during dendritic cell maturation correlate with cofilin activation and translocation to the cell membrane , 2004, European journal of immunology.

[38]  S. Joshi,et al.  Comparison of phenotypic and functional dendritic cells derived from human umbilical cord blood and peripheral blood mononuclear cells. , 2002, Journal of hematotherapy & stem cell research.

[39]  M. Kraus,et al.  Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms. , 1987, The EMBO journal.

[40]  U. Creutzig,et al.  Stem cells derived from cord blood in transplantation and regenerative medicine. , 2009, Deutsches Arzteblatt international.